Group 1: Pharmaceutical Industry - The pharmaceutical sector is expected to maintain a stable upward trend in 2026, driven by undervaluation and catalysts that could further enhance overall valuations [3][4] - Key recommendations include companies like 3SBio, Eucure Biopharma, and BeiGene, which have rich catalysts and limited impact from centralized procurement [4] - The focus will shift back to fundamentals and valuations, particularly for stocks that are currently undervalued with expected positive fundamental differences [3][4] Group 2: Real Estate Industry - The real estate sector in mainland China is projected to explore new development models under strong policy support, with expected sales area between 900-950 million square meters and sales value around 10-11 trillion RMB in 2026 [5] - In Hong Kong, key factors for market recovery include improved macro uncertainty, significant policy easing, and the return of fundamental demand drivers, with residential rental levels expected to grow by approximately 3% annually [5] - Investment preferences are ranked as state-owned enterprises with low valuations, private sector leaders with land reserves in first and second-tier cities, followed by other private developers [5] Group 3: Retail and Office Market - The retail rental market in Hong Kong is expected to see moderate growth, with community mall rents increasing by about 3-5%, while office vacancy rates have peaked, setting the stage for a rebound in 2026 [7] - The intrinsic value of the Hong Kong physical market is anticipated to gradually release, with New World Development recommended as a high-quality proxy for residential recovery [7]

Core Viewpoint - WuXi AppTec remains a focus in the capital market despite recent shareholder reductions and asset optimization initiatives, indicating that the company's long-term value foundation is solid and investor confidence in its future development remains intact [1] Group 1: Shareholder Actions and Market Response - On October 29, WuXi AppTec announced that 17 shareholders plan to reduce their holdings by no more than 2% of the total A-share capital due to personal funding needs, which is a manageable proportion [1] - By November 26, the company disclosed that from November 20 to 25, shareholders collectively reduced their holdings by 11.8279 million shares, accounting for 0.3963% of the total capital, while the stock price increased by 1.19% during this period, closing at 94.31 yuan on November 25 [1] - The company’s reduction plan complies with regulatory requirements, ensuring a transparent and orderly process, and includes a six-month lock-up period for buyers in block trades to mitigate rapid sell-off risks [1] Group 2: Financial Performance and Shareholder Returns - Since its dual listing in 2018, WuXi AppTec has demonstrated exceptional growth, with a cumulative return of 12.3 times for investors holding shares since the IPO until September 2025 [2] - The company has implemented a shareholder return plan of approximately 7 billion yuan in 2025, representing 72% of the net profit for 2024, with total shareholder returns exceeding 20 billion yuan over the past seven years, accounting for over 40% of net profits during the same period [2] - As cash flow improves, the company is expected to enhance shareholder returns further, providing solid value support for long-term investors [2] Group 3: Strategic Focus and Market Expansion - WuXi AppTec is actively optimizing its asset structure by selling its clinical business to focus on its core high-growth CRDMO business, which is expected to enhance operational efficiency and overall competitiveness [2] - The company is strategically positioning itself in the Saudi market, which is experiencing significant growth in healthcare and life sciences, leveraging its integrated CRDMO platform for future growth opportunities [3] - The company is accelerating its global layout for the CRDMO core business, with significant capacity expansions in China, the U.S., Switzerland, and Singapore, achieving a total volume of over 100,000L for peptide solid-phase synthesis reactors ahead of schedule [3] Group 4: Long-term Outlook and Industry Position - WuXi AppTec demonstrates strong adaptability and sustained profitability in a complex macro environment, with steady revenue growth and an expanding global service network [4] - The long-term development prospects for WuXi AppTec are solid, supported by the continuous growth in global drug research and development demand, and the enduring positive outlook for the CXO industry [4] - The company's unique integrated CRDMO model, diverse customer base, and proactive positioning in emerging technologies and therapies provide a robust foundation for long-term growth [4]

Report Industry Investment Rating No information provided. Core Viewpoints of the Report - In 2026, the uncertainty in the macro - environment is expected to decline. China's economic growth may be driven by rebalancing, with a slight slowdown to 4.7%. The US economy may be driven by fiscal - stimulated consumption and AI investment, and there may be three 25 - basis - point interest rate cuts by the end of next year [3][10]. - In the Chinese market, valuation growth will shift from being liquidity - driven to profit - driven. Hong Kong stocks are cost - effective. Investment should focus on high - growth stocks and core asset themes such as overseas expansion, AI, and new consumption [3][10]. - In the consumer industry, the competitive environment is expected to improve. The investment strategy is to embrace new trends and new consumption. Traditional consumer industries offer opportunities in individual stock fundamental reversals, while new consumer companies focus on valuation rebounds after improved performance certainty [3][10]. - The pharmaceutical industry is optimistic. The innovative drug and CXO sectors are recommended due to factors like China's innovative drug R & D capabilities, policy support, and expected improvement in overseas biopharmaceutical investment and financing [4][10]. - The AI industry in the technology sector will continue to grow strongly, driving the growth of multiple industries and experiencing explosive demand growth in downstream applications [4][10]. Summary According to Related Catalogs 2026 China Macroeconomic Outlook: The Road to Economic Rebalancing in the First Year of the 15th Five - Year Plan - **Core Situation in 2025**: Thanks to pre - emptive policy efforts and better - than - expected external demand, the annual economic growth target of about 5% can be achieved. However, economic development still faces challenges such as imbalance between supply and demand, the unstable real estate industry, and low inflation [11][16]. - **2026 Outlook**: - **External and Internal Uncertainties**: External trade relations between China and the US may reach a new dynamic balance, and internal risks such as local government debt and real estate have decreased [17]. - **Challenges**: Economic imbalance persists, the real estate industry remains unstable, and low inflation affects investment and consumption confidence [18][19]. - **Policy**: Fiscal policy will maintain a 4.0% budget deficit rate, issue 1.6 trillion yuan in ultra - long - term special treasury bonds, and may increase local government special bonds. It focuses on promoting consumption and stabilizing investment. Monetary policy will remain loose, with possible interest rate cuts of 10 - 20 basis points and reserve requirement ratio cuts of 50 - 100 basis points. Real estate policies will be moderately advanced [21][22]. - **Economic Growth**: Real economic growth is expected to slow to 4.7%. Consumption and investment will contribute 4.3 percentage points, higher than in 2025. The economic growth rate may be low in the first half and high in the second half. Inflation is expected to improve, with the CPI rising to 0.6% and the nominal GDP growth rate rising to 4.5%. The US dollar - RMB exchange rate will remain stable [23][24]. 2026 US Macroeconomic Outlook: The Road to Economic Recovery Led by Policy Stimulus No information provided. 2026 China Market Strategy Outlook: Demand - Driven Growth, Embracing New Core Assets - **Investment Strategy**: China's market liquidity will remain abundant, but valuation growth will be profit - driven. Hong Kong stocks are cost - effective. Investment should focus on high - growth stocks and core asset themes like overseas expansion, AI, and new consumption [10]. Consumer Industry 2026 Outlook: Find Opportunities in the Quiet and the Ordinary - **Industry Environment**: In a weak demand recovery environment, the competitive environment is expected to improve through upstream capacity reduction, downstream inventory clearance, and anti - involution [10]. - **Investment Strategy**: The key is to embrace new trends and new consumption. High - cost - performance domestic substitution, emotional consumption, health - related consumption, new retail formats, and domestic brands going overseas are important investment directions. Traditional consumer industries focus on individual stock fundamental reversals, and new consumer companies focus on valuation rebounds [10]. - **Preferred Stocks**: Pop Mart (9992.HK), Luckin Coffee (LKNCY.US), and Topsports (6110.HK) are preferred in 2026 [10]. Pharmaceutical Industry 2026 Outlook: Reach New Heights - **Optimistic Outlook**: The pharmaceutical sector is optimistic. The innovative drug sector is recommended due to China's leading R & D capabilities, policy support, and more biotech companies entering the profit stage. The CXO sector is also promising as overseas biopharmaceutical investment and financing is expected to improve [4][10]. Technology Industry 2026 Outlook: AI Algorithm Iteration Expands the Computing Power Base, and the Prosperous Ecosystem Reshapes the Growth Boundary - **AI Growth**: The AI industry will continue to grow strongly. Its underlying technology is in a flywheel - iteration stage, driving the growth of multiple industries and experiencing explosive demand growth in downstream applications such as C - end, B - end, and G - end. In the long run, it may bring growth to emerging industries like embodied intelligence [4][10].

Investment Rating - The report maintains a positive outlook on the innovative drug sector, indicating a rebound and potential for further growth in the upcoming months [3][6]. Core Insights - The innovative drug sector is expected to see a rebound after previous adjustments, with significant catalysts anticipated in December and January. The results of the national medical insurance negotiations will be released in early December, which may impact the inclusion of domestic innovative drugs in the insurance catalog [3][14]. - The upcoming American Society of Hematology (ASH) conference from December 6-9 is highlighted as a key event, with multiple differentiated hematology products expected to present new data [3][4][42]. - The CXO sector shows a continuous upward trend, supported by the rapid growth of new orders and backlog, ensuring performance release in the next 1-2 years [4][53]. Summary by Sections Innovative Drugs - The report emphasizes the importance of focusing on dual/multi-target drugs for various cancers and chronic diseases, as well as opportunities in ADCs and small nucleic acid therapies [6][15]. - The report notes that the innovative drug financing data is showing marginal improvement, indicating a potential recovery in the sector [6][15]. Biologics - The report mentions positive preliminary results from the Phase II clinical trial of amycretin for Type 2 diabetes, suggesting continued monitoring of its clinical progress [4][46]. Medical Devices - The report highlights the emergence of innovative domestic medical devices, with expectations for profit margins to stabilize and improve as new products are approved [5]. Traditional Chinese Medicine & Pharmacies - The report suggests monitoring companies with strong brand power and good inventory management, such as China Resources Sanjiu and Jichuan Pharmaceutical, due to rising flu incidence [5]. Medical Services and Consumer Healthcare - The report discusses a collaboration between a traditional Chinese medicine group and a local health bureau to enhance the capabilities of grassroots medical services through technology [5]. Key Investment Targets - The report identifies key companies to watch, including Innovent Biologics, Kintor Pharmaceutical, and others in the innovative drug and medical device sectors [7].

Core Viewpoints - The pharmaceutical sector is influenced by market pricing power and capital influx, with a focus on investment strategies for innovative drugs and related industry chains [1] - The innovative drug sector is experiencing increased liquidity and risk appetite, with a significant rise in attention towards biotech catalysts [1] - The raw material drug market is expected to see a substantial increase in demand due to patent expirations, with a projected sales impact of $390 billion from 2025 to 2030 [1] Summary by Category Innovative Drugs - The IPOs of innovative biotech companies peaked between 2019 and 2021, and the current period is critical for validating core pipelines and concept verification for second-tier pipelines [1] - The A + H share innovative drug index has seen an increase in market capitalization, which is likely to improve local financing conditions [2] Raw Material Drugs - From 2025 to 2030, the expiration of patents for over half of the top 15 small molecule drugs is expected to create a demand surge for raw materials [1] - In the first half of 2025, the production of raw materials by large-scale industrial enterprises reached 1.935 million tons, an 8.2% year-on-year increase [1] - India’s imports of raw materials and intermediates from China amounted to $1.652 billion, with a slight decrease in value but an 11.59% increase in volume, indicating a recovery in demand [1] CXO Sector - The Federal Reserve is expected to initiate a rate cut cycle, with a 90% probability of a 25 basis point cut by September 2025, which may lead to improved market liquidity [2] - The recovery in overseas demand is anticipated to boost CXO demand and performance [2] Investment Strategies - Key factors to monitor include changes in Federal Reserve interest rate policies, marginal changes in financing, gradual recovery in overseas demand, geopolitical relations, and the introduction of supportive policies for innovative drugs [3]

Core Viewpoint - The phase of broad increases in the innovative drug sector may be over, and the next two years will be a critical period for differentiation among innovative drug companies, making selective stock picking and focusing on true leaders a more suitable investment strategy [1] Group 1: Investment Strategy - The company will continue to focus on domestic commercialization and international expansion, prioritizing companies that excel in both areas rather than solely betting on business development (BD) transactions [1] - Valuations driven solely by BD are considered fragile, necessitating a careful assessment of associated risks [1] - The market tends to factor in potential total value (including milestone payments) into stock prices at the announcement of BD transactions, but the realization of milestone payments is uncertain and depends on clinical and regulatory success [1] Group 2: Sector Outlook - The company is optimistic about specific segments within innovative drugs, including Antibody-Drug Conjugates (ADC), multi-antibodies, cell and gene therapy, and autoimmune products [2] - Beyond innovative drugs, the company also sees potential in medical devices, Contract Research Organizations (CRO), and medical services [2] - The medical device sector is expected to experience significant growth in orders and inventory digestion due to increased procurement data amid a replacement trend [2] - The CRO sector is likely to benefit from the global shift towards research outsourcing, maintaining steady growth [2] - Economic recovery is anticipated to boost demand for medical services, particularly in high-end and specialized medical services [2]

Overall Viewpoint - The core viewpoint of the report emphasizes that demand is the source of strength and innovation is the light that breaks the deadlock in the pharmaceutical industry. The continuous demand for pharmaceuticals and the increasing unmet needs drive pharmaceutical companies to invest in research and development, leading to explosive revenue and stock price growth [5][7][13]. Innovation Drugs - China has become a significant participant in global innovative drug research and development, with a high-quality growth rate of therapies in development far exceeding the global average. The domestic innovative drug sector is entering a revenue era driven by innovation, creating a positive dynamic between traditional pharmaceutical companies and emerging players [5][7][27]. - The number of domestic new drug overseas authorizations has surpassed $10 billion since 2021, indicating a sustained increase in overseas authorization activity, which continues to propel China's innovative drugs into the global market [5][7][27]. Pharmaceutical Industry - The report indicates that the innovative layout in the pharmaceutical industry is beginning to yield results, with performance expected to accelerate. Many companies are transitioning to a growth phase driven by innovation, suggesting that the current period is just the beginning of a more significant performance acceleration [5][7][27]. CXO Sector - Starting in the second half of 2024, global pharmaceutical research and development demand is expected to gradually recover, with strong demand for new molecular types such as peptides and ADCs driving growth in the CDMO segment. The value of leading CRO companies is anticipated to further highlight as the difficulty and barriers in drug development increase [5][7][27]. API Sector - The core business of API companies is primarily focused on non-U.S. exports (to Europe and India), with current demand remaining strong. Leading companies are achieving positive results in expanding into CDMO businesses, and many have integrated local market formulation businesses, which are expected to benefit from the easing of centralized procurement policies [5][7][27]. Medical Devices - The high-value consumables sector is experiencing a reduction in procurement pressure, with performance expected to return to a high growth trajectory. The report highlights that the bidding for medical devices is recovering, indicating an upcoming turning point for the sector, with optimism for domestic equipment technology upgrades and international expansion [5][7][27]. Traditional Chinese Medicine - The report expresses optimism for the recovery of the traditional Chinese medicine sector in 2026, with upward factors outweighing downward ones. The expected recovery sequence for sub-sectors includes hospital-based traditional Chinese medicine, four categories of drugs, OTC common drugs, and high-value consumer traditional Chinese medicine [5][7][27]. Medical Services - The report anticipates that with the introduction of several positive macro policies, consumer expectations are likely to recover. If favorable local fiscal policies are implemented, the bad debts and payment cycles for private hospitals will also see substantial relief, alleviating market concerns [5][7][27]. Pharmaceutical Retail - The pharmaceutical retail sector has faced continuous pressure since Q3 2024, primarily due to declining demand for four categories of drugs, consumption downgrading, intensified competition, and fluctuations in medical insurance policies. However, as high baselines are gradually digested, the revenue growth of leading chains is expected to stabilize and improve [5][7][27]. Blood Products - Despite short-term performance pressures, the essential nature of blood products indicates that supply and demand are expected to rebalance. The diversity of products among companies is rapidly increasing, with high-value new products like immunoglobulin expected to drive industry growth [5][7][27]. Life Sciences Services - The life sciences services sector is experiencing a demand recovery, coupled with deepening domestic substitution and ongoing overseas expansion, leading to a positive quarterly revenue growth starting from Q4 2024. The net profit margin of the sector has been gradually improving, indicating sustained profitability [5][7][27].

Core Insights - The pharmaceutical industry is expected to reach new highs globally due to persistent human demand and unmet needs, alongside increased R&D investments by pharmaceutical companies [1] - Continuous innovation and successful outcomes are essential for pharmaceutical companies to achieve explosive revenue and stock price growth [1] Group 1: Innovative Drugs - China has seen a high-quality growth in the number of innovative therapies in development, significantly outpacing the global average, establishing itself as a key player in global innovative drug R&D [2] - Since 2021, the total overseas licensing amount for domestic new drugs has exceeded $10 billion, with ongoing growth in overseas licensing driving China's share in the global market [2] - The industry is entering an "innovation-driven" revenue era, fostering a positive dynamic between traditional pharmaceutical companies and emerging players [2] Group 2: Pharmaceutical Industry - The industry is experiencing accelerated growth as companies reap the benefits of years of R&D, with many transitioning to innovation-driven growth phases [2] - The current period is seen as just the beginning of a harvest phase, with future performance expected to further accelerate [2] Group 3: CXO Sector - Starting in the second half of 2024, global pharmaceutical R&D demand is anticipated to recover, with leading CXO companies seeing a gradual increase in orders and revenue [2] - There is strong demand for new molecular types such as peptides, small nucleic acids, and ADCs, which is driving high prosperity in the CDMO segment [2] - As drug development becomes more challenging, the value of leading CRO companies is expected to become more pronounced [2] Group 4: API Sector - API companies primarily focus on non-U.S. exports (Europe/India), with strong current demand [3] - Leading companies are achieving positive results in expanding into CDMO businesses, leveraging their robust EHS and GMP systems [3] - Many companies are also integrating local market formulation businesses, poised to benefit from easing centralized procurement pressures [3] Group 5: Medical Devices - The high-value consumables sector is expected to return to a high growth trajectory as procurement pressures ease, with innovation driving ongoing development and value reassessment [3] - The medical equipment bidding process is recovering, indicating a turning point for the sector, with optimism for domestic equipment technology upgrades and international expansion [3] - The IVD industry is under pressure, but policy disruptions are gradually clearing, allowing leading domestic companies to increase market share [3] Group 6: Traditional Chinese Medicine - The traditional Chinese medicine sector is expected to recover significantly, driven by improved chip structure, favorable policies, and inventory reduction [3] - The anticipated recovery sequence for sub-sectors includes hospital-based Chinese medicine, four categories of drugs, OTC common drugs, and high-value consumer Chinese medicine [3] Group 7: Medical Services - Positive macro policies are expected to restore consumer confidence, alleviating concerns about private hospitals' bad debts and payment cycles [4] Group 8: Pharmaceutical Retail - The pharmaceutical retail sector has faced ongoing pressure since Q3 2024 due to declining demand for four categories of drugs, consumer downgrading, and intensified competition [4] - Drugstores are responding by closing locations and enhancing efficiency, with expectations for recovery as high baseline effects are gradually digested [4] Group 9: Blood Products - Despite short-term performance pressures, the essential nature of blood products suggests a return to supply-demand balance [4] - The variety of products is increasing rapidly, with high-value new products expected to drive industry growth [4] Group 10: Life Sciences Services - The sector is seeing a recovery in demand, supported by deepening domestic substitution and ongoing international expansion, with quarterly revenue expected to turn positive from Q4 2024 [4] - The net profit margin for the sector has been improving, indicating sustained profitability growth [4]

Core Viewpoint - Despite a slowdown in the sector in the second half of the year, there remains strong interest from capital, with nearly 8 billion yuan of net inflow over five consecutive trading days, indicating a new round of investment layout [1] Group 1: Global Trends - Over the past decade, the number of pharmaceutical transactions globally has shown a steady growth trend, with multinational corporations (MNCs) needing to replenish their pipelines due to profit pressures [1] - By 2030, products with sales exceeding 5 billion USD that are nearing patent expiration will total nearly 200 billion USD, driving MNCs' enthusiasm for business development (BD) [1] Group 2: Chinese Pharmaceutical Companies - Chinese pharmaceutical companies are increasingly competitive globally, with the total amount of license-out transactions exceeding 100 billion USD this year, doubling compared to 2024 [2] - From 2015 to 2024, the number of original innovative drugs entering clinical trials from Chinese companies reached 4,382, surpassing the 4,009 from the United States, with 704 new drugs entering clinical trials in 2024, ranking first globally [2] - The number of innovative drugs developed by Chinese companies that have entered late-stage clinical trials is comparable to that of the United States [2] Group 3: Technological Trends - Antibody-drug conjugates (ADC) have become a hot topic for license-out transactions among Chinese companies over the past three years, transitioning from a follower to a leader in innovation [2] - Chinese companies are rapidly following innovations in immuno-oncology (IO) and have the potential to surpass competitors, with some products already authorized for international markets [2] Group 4: Policy Environment - The average price reduction of drugs in the 2025 medical insurance negotiations is expected to stabilize, with a significant proportion of newly added drugs being domestically produced [3] - Future centralized procurement may focus more on comprehensive value assessments rather than solely on low prices, emphasizing efficacy, quality, and patient accessibility [3] Group 5: Investment Opportunities - Focus on IO and ADC as foundational therapies for tumors, particularly with the upcoming expiration of PD-1 patents, which may lead to a market shift towards second-generation IO therapies [3] - Highlighted companies in the IO and ADC sectors include: 3SBio, Innovent Biologics, CanSino Biologics, Rongchang Biopharmaceuticals, Huahai Pharmaceutical, Yiming Pharmaceutical, Lepu Medical, Kelun-Biotech, and CSPC Pharmaceutical [3][5] - Emphasis on the internationalization of Chinese pharmaceutical companies, with a long-term view of the industry evolving into global leaders, particularly in innovative drugs and medical devices [3] - Notable companies in the medical device sector include Mindray Medical, United Imaging Healthcare, BGI Genomics, and Haitai New Light [3][5] - The CXO industry is expected to improve due to better supply-demand dynamics, with global investment recovery likely to boost client demand [4] - Key CXO leaders to watch include WuXi AppTec, WuXi Biologics, Kelun Pharmaceutical, Tigermed, and Jiuzhou Pharmaceutical [4][5]

Core Viewpoint - The CXO industry in China is experiencing a structural recovery driven by new technologies and models, moving beyond short-term profit and order recovery to a new cycle of higher added value [6][31]. Summary by Sections Introduction - The CXO industry has undergone significant fluctuations over the past five years, transitioning from a period of rapid growth to a phase of adjustment due to various external pressures [5][8]. Definition, History, and Business Model of CXO - CXO encompasses contract research organizations (CRO) and contract development and manufacturing organizations (CDMO), providing essential services throughout the drug development lifecycle [9][10][11]. - The industry evolved through three main stages: initial outsourcing in the 1960s-80s, systematic development of R&D outsourcing since the 1990s, and the rise of integrated services and new technologies in the 2010s [12][13][14]. Business Model of CXO - The growth of the CXO market is driven by global pharmaceutical R&D investment and the increasing outsourcing penetration rate [15][16]. - Global pharmaceutical R&D investment has grown from approximately $130 billion in 2010 to over $250 billion in 2023, providing a solid foundation for the industry [16]. - The outsourcing penetration rate has increased from about 30% to nearly 50% over the past decade, driven by cost efficiency and risk management [17][18]. Cycle Review: 2017-2024 - The CXO industry in China experienced a "super cycle" from 2017 to 2021, driven by domestic demand, global technology cycles, and the COVID-19 pandemic [20][22][23]. - The subsequent downturn from late 2021 to early 2024 was marked by a decline in demand, tightening global liquidity, and the natural decline of COVID-related demand [24][25][26]. New Cycle: Structural Recovery or Full Reversal? - The current recovery is characterized by a structural shift driven by new technologies, moving away from homogeneous competition to a higher value cycle [31][32]. - The recovery signals are evident from upstream drug discovery to midstream animal testing, indicating a gradual improvement in demand [33][34]. Core Drivers: New Technology Platforms - The recovery is driven by the emergence of complex, high-value new technology platforms such as ADCs and TIDES, which enhance the dependency on CXO services [35][36]. Funding Dynamics - The funding landscape has shifted from reliance on external financing to a more diversified and stable model, with domestic companies achieving profitability and increased BD activities [37][38][40]. Global Competition and Geopolitical Challenges - Chinese CXO companies maintain a competitive edge through cost advantages, efficiency, and quality improvements, despite geopolitical uncertainties [42][43][46]. - The geopolitical risks, such as the proposed BIOSECURE Act, may impact market perceptions but are unlikely to significantly affect the core operations of leading CXO firms [48]. Investment Logic in the New Cycle - The investment focus has shifted from chasing overall industry growth to identifying companies with unique competitive advantages, such as leading technology platforms and integrated service capabilities [49][50][51].